{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:19Z","timestamp":1787010199926,"version":"build-2736575974"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:p>Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system with a growing global burden. While traditionally considered rare in Asia, China rising MS prevalence and disproportionate disability present major public health challenges. Comprehensive cross-regional comparisons between China, the group of 20 (G20), and global aggregates remain limited. Using data from the global burden of disease 2021 study, we quantified MS incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in China, G20 countries, and worldwide from 1990 to 2021. Temporal trends were analyzed with joinpoint regression, drivers of burden were decomposed into epidemiological change, population aging, and population growth, and future trajectories were forecast to 2050 using autoregressive integrated moving average (ARIMA) models. To evaluate healthcare system performance, we further constructed a Quality of Care Index (QCI) based on composite ratios of incidence, prevalence, mortality, and DALYs. From 1990 to 2021, MS prevalence and DALYs increased substantially in all regions, with China exhibiting faster growth in DALYs than G20 or global averages, particularly among women and working-age adults. In contrast, the G20 showed a more pronounced aging of MS burden. Decomposition analysis revealed that population aging and epidemiological change were the primary drivers of China rising burden. Forecasting predicts continued growth of cases and DALYs through 2050. QCI analysis demonstrated global improvement in MS care quality, with China achieving marked progress, especially among elderly groups; however, persistent disparities remain, with lower QCI values in children, older adults, and women, showing a consistent \u201cmiddle-high, both-ends-low\u201d pattern across regions. The MS burden in China has expanded more rapidly than in the G20 or globally, with disproportionate impacts on women and working-age populations. Although care quality has improved, inequities by age and sex persist. These findings highlight the urgent need for earlier diagnosis, equitable access to disease-modifying treatments, and targeted interventions for vulnerable groups to mitigate the future burden of MS.<\/jats:p>","DOI":"10.1097\/md.0000000000047260","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:02:22Z","timestamp":1769191342000},"page":"e47260","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Multiple sclerosis burden and quality of care index in China and the G20 (1990\u20132021): A cross-regional analysis using global burden of disease database 2021"],"prefix":"10.1097","volume":"105","author":[{"given":"Haosen","family":"Liao","sequence":"first","affiliation":[{"name":"Liuzhou Hospital of Traditional Chinese Medicine Affiliated to the Guangxi University of Chinese Medicine, Liuzhou, Guangxi, China"},{"name":"Graduate School of Guangxi University of Chinese Medicine, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Graduate School of Guangxi University of Chinese Medicine, Nanning, China"},{"name":"The First Clinical College of Medicine, Guangxi University of Chinese Medicine, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuilan","family":"Chen","sequence":"additional","affiliation":[{"name":"Liuzhou Hospital of Traditional Chinese Medicine Affiliated to the Guangxi University of Chinese Medicine, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglu","family":"Dun","sequence":"additional","affiliation":[{"name":"Liuzhou Hospital of Traditional Chinese Medicine Affiliated to the Guangxi University of Chinese Medicine, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrui","family":"Huang","sequence":"additional","affiliation":[{"name":"Graduate School of Guangxi University of Chinese Medicine, Nanning, China"},{"name":"The First Clinical College of Medicine, Guangxi University of Chinese Medicine, Nanning, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehui","family":"Ma","sequence":"additional","affiliation":[{"name":"Liuzhou Hospital of Traditional Chinese Medicine Affiliated to the Guangxi University of Chinese Medicine, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghu","family":"Wang","sequence":"additional","affiliation":[{"name":"Liuzhou Hospital of Traditional Chinese Medicine Affiliated to the Guangxi University of Chinese Medicine, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongen","family":"Yan","sequence":"additional","affiliation":[{"name":"Liuzhou Hospital of Traditional Chinese Medicine Affiliated to the Guangxi University of Chinese Medicine, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Li","sequence":"additional","affiliation":[{"name":"Liuzhou Hospital of Traditional Chinese Medicine Affiliated to the Guangxi University of Chinese Medicine, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1704-1970","authenticated-orcid":false,"given":"Zheyi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Liuzhou Hospital of Traditional Chinese Medicine Affiliated to the Guangxi University of Chinese Medicine, Liuzhou, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260610","doi-asserted-by":"crossref","first-page":"103119","DOI":"10.1016\/j.msard.2021.103119","article-title":"Multiple sclerosis epidemiology in Asia and Oceania: a systematic review and meta-analysis.","volume":"54","author":"Forouhari","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R2-20260610","doi-asserted-by":"crossref","first-page":"e209351","DOI":"10.1212\/WNL.0000000000209351","article-title":"Prevalence and burden of multiple sclerosis in China, 1990\u20132019.","volume":"102","author":"Zhang","year":"2024","journal-title":"Neurology"},{"key":"R3-20260610","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition.","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"R4-20260610","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000533527","article-title":"A global, regional, and national survey on burden and quality of care index of multiple sclerosis: global burden of disease systematic analysis 1990-2019.","volume":"57","author":"Maroufi","year":"2023","journal-title":"Neuroepidemiology"},{"key":"R5-20260610","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12883-021-02170-3","article-title":"Socioeconomic determinants of global distribution of multiple sclerosis: an ecological investigation based on global burden of disease data.","volume":"21","author":"Moghaddam","year":"2021","journal-title":"BMC Neurol"},{"key":"R6-20260610","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1177\/13524585241265890","article-title":"Significantly increasing multiple sclerosis prevalence in Australia from 2010 to 2021.","volume":"30","author":"Campbell","year":"2024","journal-title":"Mult Scler"},{"key":"R7-20260610","doi-asserted-by":"crossref","first-page":"104696","DOI":"10.1016\/j.msard.2023.104696","article-title":"The prevalence and incidence of multiple sclerosis over the past 20 years in Northern Japan.","volume":"73","author":"Houzen","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"R8-20260610","first-page":"453","article-title":"The incidence of the multiple sclerosis in Italy: 2011-2015.","volume":"173","author":"Niglio","year":"2022","journal-title":"Clin Ter"},{"key":"R9-20260610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/nmt-2020-0010","article-title":"Multiple sclerosis and related challenges to young women\u2019s health: Canadian expert review.","volume":"10","author":"Vorobeychik","year":"2020","journal-title":"Neurodegener Dis Manag"},{"key":"R10-20260610","doi-asserted-by":"crossref","first-page":"103450","DOI":"10.1016\/j.autrev.2023.103450","article-title":"Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in women of childbearing age from 1990 to 2019.","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R11-20260610","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/13524585221129964","article-title":"Polypharmacy in multiple sclerosis: more is not necessarily better.","volume":"29","author":"Bourdette","year":"2023","journal-title":"Mult Scler"},{"key":"R12-20260610","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11910-023-01289-9","article-title":"Polypharmacy in multiple sclerosis: prevalence, risks, and mitigation strategies.","volume":"23","author":"Chapman","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R13-20260610","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/1744666X.2017.1360135","article-title":"An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future.","volume":"13","author":"Gordon-Lipkin","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"R14-20260610","doi-asserted-by":"crossref","first-page":"e209992","DOI":"10.1212\/WNL.0000000000209992","article-title":"Prevalence of, and disability due to, multiple sclerosis and neuromyelitis optica spectrum disorder in Japan by the fifth nationwide survey.","volume":"103","author":"Watanabe","year":"2024","journal-title":"Neurology"},{"key":"R15-20260610","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1186\/s12883-021-02396-1","article-title":"Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review.","volume":"21","author":"Oliva Ramirez","year":"2021","journal-title":"BMC Neurol"},{"key":"R16-20260610","doi-asserted-by":"crossref","first-page":"e70588","DOI":"10.1002\/brb3.70588","article-title":"Dementia in people with multiple sclerosis: a systematic review and meta\u2010analysis.","volume":"15","author":"Mirmosayyeb","year":"2025","journal-title":"Brain Behav"},{"key":"R17-20260610","doi-asserted-by":"crossref","first-page":"101842","DOI":"10.1016\/j.smrv.2023.101842","article-title":"The prevalence of insomnia in multiple sclerosis: a meta-analysis.","volume":"72","author":"Zeng","year":"2023","journal-title":"Sleep Med Rev"},{"key":"R18-20260610","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jocn.2023.01.006","article-title":"Prevalence of dysphagia in patients with multiple sclerosis: a systematic review and meta-analysis.","volume":"108","author":"Mirmosayyeb","year":"2023","journal-title":"J Clin Neurosci"},{"key":"R19-20260610","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00415-025-13248-0","article-title":"Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis.","volume":"272","author":"Vitturi","year":"2025","journal-title":"J Neurol"},{"key":"R20-20260610","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1093\/brain\/awad218","article-title":"The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.","volume":"146","author":"Sharmin","year":"2023","journal-title":"Brain"},{"key":"R21-20260610","doi-asserted-by":"crossref","first-page":"zsae186","DOI":"10.1093\/sleep\/zsae186","article-title":"Insufficient sleep: another risk factor for multiple sclerosis.","volume":"47","author":"Aoun","year":"2024","journal-title":"Sleep"},{"key":"R22-20260610","doi-asserted-by":"crossref","first-page":"840158","DOI":"10.3389\/fimmu.2022.840158","article-title":"Smoking attributable risk in multiple sclerosis.","volume":"13","author":"Manouchehrinia","year":"2022","journal-title":"Front Immunol"},{"key":"R23-20260610","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1177\/13524585241274527","article-title":"Misdiagnosis and underdiagnosis of multiple sclerosis: a systematic review and meta-analysis.","volume":"30","author":"Z\u00fcrrer","year":"2024","journal-title":"Mult Scler"},{"key":"R24-20260610","doi-asserted-by":"crossref","first-page":"1285103","DOI":"10.3389\/fpubh.2023.1285103","article-title":"Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis.","volume":"11","author":"Vitturi","year":"2023","journal-title":"Front Public Health"},{"key":"R25-20260610","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","article-title":"High-efficacy therapies for treatment-na\u00efve individuals with relapsing\u2013remitting multiple sclerosis.","volume":"36","author":"Freeman","year":"2022","journal-title":"CNS Drugs"},{"key":"R26-20260610","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1007\/s10072-022-06126-4","article-title":"The incidence and prevalence, diagnosis, and treatment of multiple sclerosis in China: a narrative review.","volume":"43","author":"Jia","year":"2022","journal-title":"Neurol Sci"},{"key":"R27-20260610","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S1474-4422(24)00288-6","article-title":"Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, Northern Europe, and Australasia.","volume":"23","author":"Amezcua","year":"2024","journal-title":"Lancet Neurol"},{"key":"R28-20260610","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1177\/13524585231197076","article-title":"Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences.","volume":"29","author":"Uher","year":"2023","journal-title":"Mult Scler"},{"issue":"8 Suppl","key":"R29-20260610","first-page":"S211","article-title":"The current landscape and unmet needs in multiple sclerosis.","volume":"16","author":"Markowitz","year":"2010","journal-title":"Am J Manag Care"},{"key":"R30-20260610","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review.","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"R31-20260610","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1097\/JS9.0000000000002464","article-title":"Trends and projections of the burden of gastric cancer in China and G20 countries: a comparative study based on the global burden of disease database 2021.","volume":"111","author":"Yang","year":"2025","journal-title":"Int J Surg"},{"key":"R32-20260610","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R33-20260610","doi-asserted-by":"crossref","first-page":"e70444","DOI":"10.1002\/alz.70444","article-title":"Alzheimer\u2019s disease and dementia in Japan: epidemiological trends, regional disparities, and future projections.","volume":"21","author":"Behera","year":"2025","journal-title":"Alzheimers Dement"},{"key":"R34-20260610","doi-asserted-by":"crossref","first-page":"1571916","DOI":"10.3389\/fnut.2025.1571916","article-title":"Analysis of diet-related stroke disease burden in China from 1990 to 2021 and projections for 2025-2044.","volume":"12","author":"Wang","year":"2025","journal-title":"Front Nutr"},{"key":"R35-20260610","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/eurpub\/ckq120","article-title":"The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival.","volume":"21","author":"Asadzadeh Vostakolaei","year":"2011","journal-title":"Eur J Public Health"},{"key":"R36-20260610","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nbt0308-303","article-title":"What is principal component analysis?","volume":"26","author":"Ringn\u00e9r","year":"2008","journal-title":"Nat Biotechnol"},{"key":"R37-20260610","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000492819","article-title":"Global and regional trends of multiple sclerosis disability-adjusted life years rates: a 25-year assessment.","volume":"52","author":"Mansouri","year":"2019","journal-title":"Neuroepidemiology"},{"key":"R38-20260610","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2015.00520","article-title":"Infection as an environmental trigger of multiple sclerosis disease exacerbation.","volume":"6","author":"Steelman","year":"2015","journal-title":"Front Immunol"},{"key":"R39-20260610","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11910-022-01211-9","article-title":"Multiple sclerosis management during the COVID-19 pandemic.","volume":"22","author":"Hollen","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R40-20260610","doi-asserted-by":"crossref","first-page":"103326","DOI":"10.1016\/j.autrev.2023.103326","article-title":"Global burden and cross-country inequalities in autoimmune diseases from 1990 to 2019.","volume":"22","author":"Cao","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R41-20260610","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the global burden of disease study 2016.","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"R42-20260610","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/14737175.2018.1481390","article-title":"Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics.","volume":"18","author":"Collongues","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"R43-20260610","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","article-title":"Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region.","volume":"80","author":"Hittle","year":"2023","journal-title":"JAMA Neurol"},{"key":"R44-20260610","doi-asserted-by":"crossref","first-page":"e230016","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.","volume":"12","author":"Samjoo","year":"2023","journal-title":"J Comp Eff Res"},{"key":"R45-20260610","doi-asserted-by":"crossref","first-page":"103932","DOI":"10.1016\/j.msard.2022.103932","article-title":"Multiple sclerosis incidence: a systematic review of change over time by geographical region.","volume":"63","author":"Lane","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R46-20260610","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/WNF.0000000000000612","article-title":"A real-world experience of rituximab: a panacea in therapy of multiple sclerosis in low- and middle-income settings.","volume":"47","author":"Raja","year":"2024","journal-title":"Clin Neuropharmacol"},{"key":"R47-20260610","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1177\/13524585211066598","article-title":"Cognitive dysfunction and mortality in multiple sclerosis: long-term retrospective review.","volume":"28","author":"Cavaco","year":"2022","journal-title":"Mult Scler"},{"key":"R48-20260610","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13559","article-title":"Standardized mortality ratios in multiple sclerosis: systematic review with meta-analysis.","volume":"145","author":"Smyrke","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"R49-20260610","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1177\/1352458519849513","article-title":"A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.","volume":"26","author":"Pellegrini","year":"2020","journal-title":"Mult Scler"},{"key":"R50-20260610","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/1352458516672017","article-title":"Personalised medicine for multiple sclerosis care.","volume":"23","author":"Gafson","year":"2017","journal-title":"Mult Scler"},{"key":"R51-20260610","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/jnnp-2022-328932","article-title":"Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia.","volume":"93","author":"Simpson-Yap","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R52-20260610","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/brain\/awab104","article-title":"The latitude gradient for multiple sclerosis prevalence is established in the early life course.","volume":"144","author":"Sabel","year":"2021","journal-title":"Brain"},{"key":"R53-20260610","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1136\/jnnp-2018-320189","article-title":"Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis.","volume":"90","author":"Simpson","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R54-20260610","doi-asserted-by":"crossref","first-page":"e1105","DOI":"10.1212\/NXI.0000000000001105","article-title":"COVID-19 severity in multiple sclerosis: putting data into context.","volume":"9","author":"Sormani","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R55-20260610","doi-asserted-by":"crossref","first-page":"e37297","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment.","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R56-20260610","doi-asserted-by":"crossref","first-page":"eaav7188","DOI":"10.1126\/science.aav7188","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.","volume":"365","year":"2019","journal-title":"Science"},{"key":"R57-20260610","doi-asserted-by":"crossref","first-page":"e066335","DOI":"10.1136\/bmjopen-2022-066335","article-title":"Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the global burden of disease study 2019.","volume":"12","author":"Li","year":"2022","journal-title":"BMJ Open"},{"key":"R58-20260610","doi-asserted-by":"crossref","first-page":"105085","DOI":"10.1016\/j.msard.2023.105085","article-title":"Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: a combined survey and insurance claims study.","volume":"80","author":"Meltzer","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"R59-20260610","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the global burden of disease study 2021.","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"R60-20260610","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe.","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult Scler J"},{"key":"R61-20260610","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.pec.2022.07.013","article-title":"Communication between persons with multiple sclerosis and their health care providers: a scoping review.","volume":"105","author":"Thompson","year":"2022","journal-title":"Patient Educ Couns"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:03:20Z","timestamp":1781085800000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047260","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-09-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}